RNA-based Therapeutics and Vaccines Market Size 2022-28: Growth, Trends, Global Share Analysis

According to Precision Business Insights (PBI) latest report, the global RNA-based therapeutics and vaccines market was valued at USD 61,296.3 million in 2021 and growing at a significant CAGR of 3.8% over 2022-2028. RNA vaccines provide multiple advantages compared to DNA vaccines in terms of production, administration, and safety and have been shown to be promising in clinical trials involving humans, which have increased the demand of RNA based therapeutics and vaccine market. Increasing focus of legislative bodies on developing reimbursement policies has fueled the development process RNA's molecules. The technologies that are being readily adopted include Smart technology, antisense technology, and RNAi interference technology. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/rna-based-therapeutics-and-vaccines-market/

RNA-Based Therapeutics Segment Dominates the RNA based Therapeutics and Vaccines Market:
By application, the RNA based therapeutics market is segmented into genetic disorders and auto immune disorders. Genetic disorders segment accounted for a majority of market share in the global RNA based therapeutics market in 2021 and expected to remain dominant during the forecast period, owing to surge in case of genetic diseases, rare disorders, and molecular diagnostics. These factors are expected to further fuel the demand for RNA based therapeutic.

North America Leads RNA based Therapeutics and Vaccines Market:
RNA based therapeutics and vaccines market accounts major share in North America due to the increasing importance of RNA drugs in treating rare medical diseases. The U.S. is expected to remain dominant over other countries during the forecast period. RNA based Therapeutics and Vaccines market find substantial application in Europe due to increasing RNA research activities in association with government organizations. The high prevalence of infectious diseases in the Asia Pacific is expected to offer huge opportunities for RNA based Therapeutics and Vaccines market.

Strategic New Product Launches, Mergers, Acquisitions and Agreements are the key strategies adopted by market players:
The global RNA based therapeutics and vaccines market further reveals that the key players increasingly adopting strategies such as launch of newer products, product launches, and long-term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance, In Jan 2022, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development. In August 2021, as part of Sanofi's endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=38090

The RNA based therapeutics and vaccines market is segmented based on type, application, end-user, and geography.
Based on the Type, the market is segmented into the following:
• RNA-Based Therapeutics
• RNA-Based Vaccines

Based on the Application, the market is segmented into the following:
• Genetic Disorders
• Auto-immune disorders

Based on the End-user, the market is segmented into the following:
• Diagnostic Centers
• Hospitals
• Academic & Research Institutes
• Forensic Science Laboratories
• CROs (Contract Research Organizations)

Request Methodology: https://precisionbusinessinsights.com/request-methodology?product_id=38090

Key player's profiles in the RNA based therapeutics and vaccines market report are Alnylam Pharmaceuticals, Inc, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc, BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc, Marina Biotech, Inc, miRagen Therapeutics, Inc, Moderna, Inc, Quark Pharmaceuticals, Inc, Regulus Therapeutics, Inc, Sylentis S.A.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.